During any one single trading day a maximum of 25% of the average
daily trading volume of Lundbeck shares on the Copenhagen Stock
Exchange, calculated over 20 days prior to each trading date, will be
bought back, as the share buyback program is implemented in
accordance with the provisions of the European Commission's
regulation no. 2273/2003 of December 22, 2003.
At least once every seven trading days, Lundbeck will issue an
announcement in respect of the transactions made under the program.
The following transactions have been made under the program:
No. of shares Average Transaction value
purchase price (DKK)
(DKK)
Accumulated, last 24,141,977 135.2722 3,265,738,364
announcement
19 November 2007 104,061 145.9047 15,182,993.45
20 November 2007 40,159 144.1499 5,788,914.71
21 November 2007 103,312 145.6913 15,051,664.59
22 November 2007 102,187 144.8327 14,800,022.39
23 November 2007 -- -- --
26 November 2007 104,292 145.9896 15,225,549.12
27 November 2007 41,092 145.8278 5,992,354.14
Accumulated under the 24,637,080 135.4779 3,337,779,862
program
Following the above buyback it is hereby announced that Lundbeck owns
a total of 5,480,293 own shares at a nominal value of DKK 5, equal to
2.64% of the total number of 207,279,631 shares.
The content of this release will have no influence on the Lundbeck
Group's financial result for 2007.
Lundbeck contacts
Investors: Media:
Jacob Tolstrup Anders Schroll
Director, Corporate Reporting Head of Communication
+45 36 43 30 79 +45 36 43 20 81
________________________
Stock Exchange Release No 311 - 27 November 2007
About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2006,
the company's revenue was DKK 9.2 billion (approximately EUR 1.2
billion or USD 1.6 billion). The number of employees is approximately
5,300 globally. For further information, please visit
www.lundbeck.com
